Dyne Therapeutics (DYN) Stock Forecast & Price Target

Compare

362 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

DYN Analyst Ratings

Strong Buy

12 Buy

2 Hold

0 Sell

Based on 14 analysts giving stock ratings to

Dyne

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

DYN Stock 12 Month Forecast

Average Price Target

$33.68

▲(221.68% Upside)

Based on 14 Wall Street analysts offering 12 month price targets for Dyne Therapeutics in the last 3 months. The average price target is $33.68 with a high forecast of $50.00 and a low forecast of $9.00. The average price target represents a 221.68% change from the last price of $10.47.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","18":"$18","29":"$29","40":"$40","51":"$51"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33.68,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$33.68</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,18,29,40,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.05,13.123076923076924,16.196153846153848,19.26923076923077,22.342307692307692,25.415384615384617,28.48846153846154,31.561538461538465,34.63461538461539,37.70769230769231,40.78076923076924,43.85384615384616,46.926923076923075,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.05,11.867692307692309,13.685384615384617,15.503076923076923,17.32076923076923,19.13846153846154,20.956153846153846,22.773846153846154,24.591538461538462,26.40923076923077,28.22692307692308,30.044615384615387,31.86230769230769,{"y":33.68,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.05,9.96923076923077,9.88846153846154,9.807692307692308,9.726923076923077,9.646153846153847,9.565384615384616,9.484615384615385,9.403846153846153,9.323076923076924,9.242307692307692,9.161538461538461,9.080769230769231,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":42.08,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.09,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.76,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.74,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.28,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.56,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.22,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.61,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.23,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.99,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.7,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.68,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.05,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$50.00

Average Price Target$33.68

Lowest Price Target$9.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Paul MatteisStifel Nicolaus

Stifel Nicolaus

$36

Buy

243.84%

Upside

Reiterated

08/04/25

Stifel Nicolaus Remains a Buy on Dyne Therapeutics (DYN)Stifel analyst Paul Matteis reiterated a Buy rating and $36.00 price target on Dyne Therapeutics (NASDAQ: DYN).

Michael UlzMorgan Stanley

Morgan Stanley

$48

Buy

358.45%

Upside

Reiterated

08/04/25

Dyne Therapeutics: Promising Advancements and FDA Support Drive Buy Rating

Martin AusterRaymond James

Raymond James

$37→$31

Buy

196.08%

Upside

Reiterated

07/29/25

Dyne Therapeutics price target lowered to $31 from $37 at Raymond JamesDyne Therapeutics price target lowered to $31 from $37 at Raymond James

Ananda GhoshH.C. Wainwright

H.C. Wainwright

$38

Buy

262.94%

Upside

Reiterated

07/29/25

Dyne Therapeutics: Promising Clinical Developments and Strategic Positioning Drive Buy RatingValuations and Risks. Our price target of $38 is based on an equally weighted composite of: (a) $41/share, as a 25x multiple of taxed and diluted 2034 EPS of $6/ share discounted back to and (b) an NPV discounted cash flow of $36/share, with a discount rate of 12% and growth rate of 2%. These assumptions are in line with the expected P/E multiple and discount rates of an early developmental-stage biopharmaceutical company.

Kostas BiliourisBMO Capital

BMO Capital

$50

Buy

377.55%

Upside

Reiterated

07/29/25

Dyne Therapeutics: Strategic Advancements and Financial Stability Drive Buy Rating

Louise ChenScotiabank

Scotiabank

$50

Buy

377.55%

Upside

Reiterated

07/29/25

Dyne Therapeutics (DYN) Gets a Buy from Scotiabank

Luca IssiRBC Capital

RBC Capital

$25→$23

Buy

119.68%

Upside

Reiterated

07/29/25

Dyne Therapeutics price target lowered to $23 from $25 at RBC CapitalDyne Therapeutics price target lowered to $23 from $25 at RBC Capital

Keay NakaeChardan Capital

Chardan Capital

$50→$38

Buy

262.94%

Upside

Reiterated

07/28/25

Chardan Capital Sticks to Its Buy Rating for Dyne Therapeutics (DYN)

Tessa RomeroJ.P. Morgan

J.P. Morgan

$10→$9

Hold

-14.04%

Downside

Reiterated

07/15/25

J.P. Morgan Keeps Their Hold Rating on Dyne Therapeutics (DYN)

Gavin Clark-GartnerEvercore ISI

Evercore ISI

$46→$41

Buy

291.60%

Upside

Reiterated

07/11/25

Dyne Therapeutics price target lowered to $41 from $46 at Evercore ISIDyne Therapeutics price target lowered to $41 from $46 at Evercore ISI

William PickeringBernstein

Bernstein

$13→$11.5

Hold

9.84%

Upside

Reiterated

07/02/25

Bernstein Keeps Their Hold Rating on Dyne Therapeutics (DYN)

Catherine NovackJonesTrading

JonesTrading

$30

Buy

186.53%

Upside

Initiated

06/25/25

Dyne Therapeutics initiated with a Buy at JonesResearchDyne Therapeutics initiated with a Buy at JonesResearch

Brian SkorneyRobert W. Baird

Robert W. Baird

$46→$32

Buy

205.64%

Upside

Reiterated

06/18/25

Dyne Therapeutics price target lowered to $32 from $46 at BairdDyne Therapeutics price target lowered to $32 from $46 at Baird

Andreas ArgyridesOppenheimer

Oppenheimer

$60→$34

Buy

224.74%

Upside

Initiated

06/02/25

Dyne Therapeutics assumed with an Outperform at OppenheimerDyne Therapeutics assumed with an Outperform at Oppenheimer

Edward TenthoffPiper Sandler

Piper Sandler

$48

Buy

358.45%

Upside

Reiterated

04/14/25

Dyne Therapeutics (DYN) Receives a Buy from Piper Sandler

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Paul MatteisStifel Nicolaus

Stifel Nicolaus

$36

Buy

243.84%

Upside

Reiterated

08/04/25

Stifel Nicolaus Remains a Buy on Dyne Therapeutics (DYN)Stifel analyst Paul Matteis reiterated a Buy rating and $36.00 price target on Dyne Therapeutics (NASDAQ: DYN).

Michael UlzMorgan Stanley

Morgan Stanley

$48

Buy

358.45%

Upside

Reiterated

08/04/25

Dyne Therapeutics: Promising Advancements and FDA Support Drive Buy Rating

Martin AusterRaymond James

Raymond James

$37→$31

Buy

196.08%

Upside

Reiterated

07/29/25

Dyne Therapeutics price target lowered to $31 from $37 at Raymond JamesDyne Therapeutics price target lowered to $31 from $37 at Raymond James

Ananda GhoshH.C. Wainwright

H.C. Wainwright

$38

Buy

262.94%

Upside

Reiterated

07/29/25

Kostas BiliourisBMO Capital

BMO Capital

$50

Buy

377.55%

Upside

Reiterated

07/29/25

Dyne Therapeutics: Strategic Advancements and Financial Stability Drive Buy Rating

Louise ChenScotiabank

Scotiabank

$50

Buy

377.55%

Upside

Reiterated

07/29/25

Dyne Therapeutics (DYN) Gets a Buy from Scotiabank

Luca IssiRBC Capital

RBC Capital

$25→$23

Buy

119.68%

Upside

Reiterated

07/29/25

Dyne Therapeutics price target lowered to $23 from $25 at RBC CapitalDyne Therapeutics price target lowered to $23 from $25 at RBC Capital

Keay NakaeChardan Capital

Chardan Capital

$50→$38

Buy

262.94%

Upside

Reiterated

07/28/25

Chardan Capital Sticks to Its Buy Rating for Dyne Therapeutics (DYN)

Tessa RomeroJ.P. Morgan

J.P. Morgan

$10→$9

Hold

-14.04%

Downside

Reiterated

07/15/25

J.P. Morgan Keeps Their Hold Rating on Dyne Therapeutics (DYN)

Gavin Clark-GartnerEvercore ISI

Evercore ISI

$46→$41

Buy

291.60%

Upside

Reiterated

07/11/25

Dyne Therapeutics price target lowered to $41 from $46 at Evercore ISIDyne Therapeutics price target lowered to $41 from $46 at Evercore ISI

William PickeringBernstein

Bernstein

$13→$11.5

Hold

9.84%

Upside

Reiterated

07/02/25

Bernstein Keeps Their Hold Rating on Dyne Therapeutics (DYN)

Catherine NovackJonesTrading

JonesTrading

$30

Buy

186.53%

Upside

Initiated

06/25/25

Dyne Therapeutics initiated with a Buy at JonesResearchDyne Therapeutics initiated with a Buy at JonesResearch

Brian SkorneyRobert W. Baird

Robert W. Baird

$46→$32

Buy

205.64%

Upside

Reiterated

06/18/25

Dyne Therapeutics price target lowered to $32 from $46 at BairdDyne Therapeutics price target lowered to $32 from $46 at Baird

Andreas ArgyridesOppenheimer

Oppenheimer

$60→$34

Buy

224.74%

Upside

Initiated

06/02/25

Dyne Therapeutics assumed with an Outperform at OppenheimerDyne Therapeutics assumed with an Outperform at Oppenheimer

Edward TenthoffPiper Sandler

Piper Sandler

$48

Buy

358.45%

Upside

Reiterated

04/14/25

Dyne Therapeutics (DYN) Receives a Buy from Piper Sandler

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Dyne Therapeutics

1 Month

xxx

Success Rate

8/15 ratings generated profit

Average Return

+3.28%

reiterated a xxx

rating 11 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 53.33% of your transactions generating a profit, with an average return of +3.28% per trade.

3 Months

xxx

Success Rate

3/6 ratings generated profit

Average Return

-3.92%

reiterated a xxx

rating 12 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of -3.92% per trade.

1 Year

Keay NakaeChardan Capital

Success Rate

8/15 ratings generated profit

Average Return

+34.85%

reiterated a buy rating 11 days ago

Copying Keay Nakae's trades and holding each position for 1 Year would result in 53.33% of your transactions generating a profit, with an average return of +34.85% per trade.

2 Years

xxx

Success Rate

7/17 ratings generated profit

Average Return

+51.69%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 41.18% of your transactions generating a profit, with an average return of +51.69% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DYN Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, DYN has received 23 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. DYN average Analyst price target in the past 3 months is 33.68.

Each month's total comprises the sum of three months' worth of ratings.

DYN Financial Forecast

DYN Earnings Forecast

Next quarter’s earnings estimate for DYN is -$0.85 with a range of -$1.14 to -$0.64. The previous quarter’s EPS was -$0.97. DYN beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.03% of the time in the same period. In the last calendar year DYN has Preformed in-line its overall industry.

No data currently available

DYN Sales Forecast

Next quarter’s sales forecast for DYN is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. DYN beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.64% of the time in the same period. In the last calendar year DYN has Preformed in-line its overall industry.

DYN Stock Forecast FAQ

What is DYN’s average 12-month price target, according to analysts?

Based on analyst ratings, Dyne Therapeutics, Inc.’s 12-month average price target is 33.68.

What is DYN’s upside potential, based on the analysts’ average price target?

Dyne Therapeutics, Inc. has 221.68% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is DYN a Buy, Sell or Hold?

Dyne Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 12 buy ratings, 2 hold ratings and 0 sell ratings.

What is Dyne Therapeutics, Inc.’s price target?

The average price target for Dyne Therapeutics, Inc. is 33.68. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $50.00 ,the lowest forecast is $9.00. The average price target represents 221.68% Increase from the current price of $10.47.

What do analysts say about Dyne Therapeutics, Inc.?

Dyne Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of DYN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Dyne Therapeutics (DYN) Stock Forecast & Price Target

DYN Analyst Ratings

DYN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Dyne Therapeutics

DYN Analyst Recommendation Trends

DYN Financial Forecast

DYN Earnings Forecast

DYN Sales Forecast

DYN Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts